Evidence map›Paper›PMID 40148468›Full record

ArticleCell death and differentiation2025

The transcription factor LHX2 mediates and enhances oncogenic BMP signaling in medulloblastoma.

Yae Ohata, Mohamad M Ali, Yutaro Tsubakihara, Yuka Itoh, Gabriela Rosén, Tobias Bergström, Anita Morén, Irene Golán-Cancela, Ayana Nakada, Oleksandr Voytyuk and 14 more

Abstract read
In one paragraph

Article in Cell death and differentiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yae OhataDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Mohamad M AliDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-4902-0550
Yutaro TsubakiharaDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Yuka ItohDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Gabriela RosénDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Tobias BergströmDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Anita MorénDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Irene Golán-CancelaDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Ayana NakadaDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Oleksandr VoytyukDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.
Maiko TsuchiyaDepartment of Oral Pathology, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.
Rei FukuiDepartment of Pathology, Nihon University School of Dentistry, Chiyoda-ku, Tokyo, Japan.
Kouhei YamamotoDepartment of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Paula Martín-RubioTranslational Research Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.ORCID 0000-0002-2702-9212
Patricia SanchoTranslational Research Unit, Hospital Universitario Miguel Servet, IIS Aragon, Zaragoza, Spain.
Carina StrellDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Patrick MickeDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Robert J Wechsler-ReyaHerbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Yoshinobu HashizumeRIKEN Program for Drug Discovery and Medical Technology Platforms, Wako, Saitama, Japan.
Kohei MiyazonoDepartment of Applied Pathology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0001-7341-0172
Laia CajaDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-8786-8763
Carl-Henrik HeldinDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-9508-896X
Fredrik J SwartlingDepartment of Immunology, Genetics and Pathology, Rudbeck Laboratory, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-8460-4367
Aristidis MoustakasDepartment of Medical Biochemistry and Microbiology, Science for Life Laboratory, Box 582, Biomedical Center, Uppsala University, Uppsala, Sweden. aris.moustakas@imbim.uu.se.ORCID 0000-0001-9131-3827

Funding

Identifying and Targeting the Drivers of Pediatric Brain TumorsR35NS122339 · NINDS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Robert J. Wechsler-Reya · 2021 to 2026
$3.6M
Barncancerfonden (Swedish Childhood Cancer Foundation) PR2018-0091, PR2020-0088, PR2023-0115Barncancerfonden (Swedish Childhood Cancer Foundation) TJ2021-0078Cancerfonden (Swedish Cancer Society) 22 0555 01HEC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 787472Ludwig Institute for Cancer Research (Ludwig Cancer Research) Uppsala BranchMagnus Bergvalls Stiftelse (Magnus Bergvall Foundation) 2021-04284, 2022-211MEXT | Japan Society for the Promotion of Science (JSPS) Overseas Research FellowshipNINDS NIH HHS R35 NS122339Sasakawa Memorial Health Foundation (SMHF) GA21-JPN-0018Stiftelsen Lars Hiertas Minne (Lars Hierta Memorial Foundation) FO2020-0335Vetenskapsrådet (Swedish Research Council) 2020-01291
6 · The paper itself

Abstract

Oncogenic events perturb cerebellar development leading to medulloblastoma, a common childhood brain malignancy. Molecular analyses classify medulloblastoma into the WNT, SHH, Group 3 and Group 4 subgroups. Bone morphogenetic protein (BMP) pathways control cerebellar development and have been linked to the progression of medulloblastoma disease, with major remaining gaps in their mechanistic and clinically-relevant roles. We therefore aimed at exploring BMP mechanisms of action in medulloblastoma. Patient-derived tumors from different subgroups were analyzed in mouse xenografts, complemented by independent tumor immunohistochemical analysis. Cell-based assays analyzed signaling mechanisms. Medulloblastoma cell orthotopic xenografts analyzed tumor growth and metastasis in vivo. Active BMP signaling, detected as nuclear and phosphorylated SMAD1/5, characterized several medulloblastoma subgroups, with enrichment in Group 4, SHH and Group 3 tumors. Spatial transcriptomics in tumor areas, complemented by transcriptomic analysis of multiple cell models, identified BMP-dependent transcriptional induction of the LIM-homeobox gene 2 (LHX2). BMP signaling via SMADs induced LHX2 expression and LHX2 transcriptionally induced BMP type I receptor (ACVR1) expression by association with the proximal promoter region of the ACVR1 gene. BMP signaling and LHX2 gain-of-function expression led to enriched stemness and associated chemoresistance in medulloblastoma cultures. In-mouse orthotopic transplantation of paired primary/recurrent Group 4 medulloblastoma cell populations, correspondingly expressing LHX2-low/BMP-low signaling and LHX2-high/BMP-high signaling, ascribed to the latter (high) group more efficient tumor propagation and spinal cord metastatic potential. Depletion of LHX2 in these recurrent tumor cells suppressed both BMP signaling and tumor propagation in vivo. Thus, LHX2 cooperates with, and enhances, oncogenic BMP signaling in medulloblastoma tumors. The molecular pathway that couples LHX2 function to BMP signaling in medulloblastoma deepens our understanding this malignancy.

Indexed as

Bone Morphogenetic ProteinsCerebellar NeoplasmsLIM-Homeodomain ProteinsMedulloblastomaTranscription FactorsActivin Receptors, Type IAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceSignal TransductionActivin Receptors, Type IACVR1 protein, humanBone Morphogenetic ProteinsLHX2 protein, humanLIM-Homeodomain ProteinsTranscription Factors

Identifiers

PMID40148468
PMCPMC12501261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.